Pulmonary HTN and cor pulmonale Flashcards
(33 cards)
What do these symptoms indicate?
Progressive or unexplained dyspnea, fatigue, angina, weakness, syncope, peripheral edema, abdominal distention, orthopnea, dry cough, exercise induced N/V, hypoxia
Rarely – hemoptysis, hoarseness, palpitations
pulmonary HTN
What are risk factors for pulmonary HTN?
Women>men
30s-60s
CAD, COPD
BMPR2 gene defect
What is defined by Increased mean pulmonary arterial pressure >20 or 25 on resting cardiac cath from diseases, drugs, toxins, genetic abnormalities, idiopathic
pulmonary HTN
elevation in pulmonary artery system alone
pre-capillary pulmonary HTN
pressure elevation within the pulmonary venous + capillary systems
post-capillary pulmonary HTn
PE: prominent pulmonary component of S2
- pansystolic tricuspid regurg murmur
- diastolic pulmonary regurg murmur (Graham-Steel)
- third heart sound (RV dysfunction)
pulmonary HTN
What’s your initial test of choice when suspecting pulmonary HTN?
TTE
What’s your gold standard for confirming pulmonary HTN?
right heart cath - can also separate group 1 from others
When can you diagnose pulmonary HTN?
mPAP>/ 25 at rest. 20 per current
What do these indicate:
EKG - RVH, RAE, peaked P wave, could be normal!
CXR - RV and RAE
PFT: Group 1 = decreased DLCO
Labs – BNP elevated
pulmonary HTN
Systolic PAP of 35-40 or higher on echo
pulmonary HTN
Oxygenation studies and/or high resolution CT to diagnose
group 2 or group 3
What test do you do after right heart cath?
Vasodilation testing w/ NO or CCBs after→ significant acute vasodilation response = MPP >10/20% to <40 (helping with treatment)
Group 1
pulmonary arterial HTN (PAH)
Group 2
pulmonary HTN due to left heart disease
Group 3
pulmonary HTN due to lung diseases and/or hypoxia
Group 4
pulmonary HTN due to pulmonary artery obstructions (mainly chronic thromboembolic pulmonary HTN (CTEPH))
Group 5
pulmonary HTN with unclear and/or multifactorial mechanisms
How do you manage pulmonary HTN first?
REFER to pulmonologist (1st) and cardiologist (2nd)
- Nitric oxide pathway w/ phosphodiesterase inhibitors (sildenafil, tadalafil)
- soluble guanylate cyclase stimulators (riociguat)
- Endothelin pathway: endothelin receptor antagonists (bosentan, ambrisentan, macitentan)
- Prostacyclin pathway: IV epoprostenol, treprostinil, inhaled iloprost, selexipag
vasodilators for treating Group 1 that is unable to be treated with CCBs or NO
Tx: group 1 (responsive)
CCBs
tx: group 2 and 3
Treat underlying conditions
NO PAH-specific therapies
tx: group 4
Treat w/ lifelong anticoagulation
Pulmonary endarterectomy (PEA) w/ surgically accessible CTEPH when possible
OR balloon pulmonary artery angioplasty in ineligible
Avoid CCBs
tx: group 5
Treat underlying disorder